Moe Yamamoto’s scientific contributions

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (1)


Schematic illustration of the crossover design of Study 1
Schematic illustration of the crossover design of Study 2
Graphs presenting OUES and VO2max during ramp-incremental cycling test in Study 1. (a) OUES and (b) VO2max during ramp-incremental cycling test on day 1 and 8 in Study 1. Data are presented as means ± SE and individual responses. *P < 0.05 versus placebo, †P < 0.05 versus 2.5 mg KMP, MMRM for crossover design
Graphs presenting VO2/VE and RPE during constant-load cycling test in Study 2. (a) VO2/VE and (b) RPE during constant-load cycling test at each exercise intensity. White bar, placebo; grey bar, KMP. Data are presented as means ± SE and individual responses. *P < 0.05 versus placebo corresponding to exercise intensity, MMRM for crossover design
Kaempferol enhances oxygen utilization efficiency during maximal incremental and constant-load exercises in healthy men: a randomized trial
  • Article
  • Full-text available

November 2024

·

19 Reads

Yasutaka Ikeda

·

Aina Gotoh-Katoh

·

Moe Yamamoto

·

[...]

·

Minoru Akiyama

Background Hypoxia can occur in daily life, and exercise is a potential trigger. Intense exercise increases oxygen demand in muscles, potentially compromising performance by reducing ATP resynthesis. Kaempferol (KMP) increases intracellular ATP resynthesis in hypoxic cellular models. Aims We investigated the effects of KMP on oxygen utilization during exercise in a general human population. Methods Study 1 (Ramp-incremental cycling test): Overall, 20 men were randomized to four groups and administrated placebo, 2.5, 10, or 25 mg KMP for 8 days in a crossover design. Measurements of oxygen utilization efficiency slope (OUES), maximal oxygen uptake (VO2max), peak heart rate (HR), VO2 and work rate at gas-exchange threshold, minute ventilation/carbon dioxide output ratio (VE/VCO2) slope, and post-exercise muscle tightness and breathing difficulty were performed on days 1 and 8. Study 2 (Constant-load cycling test): Overall, 25 men were randomized to groups that received either a single dose of 10 mg KMP or a placebo in a crossover design. VO2/VE, VO2max, VO2, respiratory rate, HR, respiratory exchange ratio, and VE/VCO2 were measured at exercise intensities of 25%, 50%, and 75% of VO2max. Results Study 1: Both OUES and VO2max showed significant dose-dependent increase on day 1. The optimal dose and frequency for the ergogenic effects of KMP was found to be 10 mg in a single intake. Study 2: KMP improved VO2/VE and enhanced respiratory and cardiovascular indices. Conclusions KMP enhances the maximum capacity for oxygen utilization and improves oxygen utilization efficiency at several exercise levels. Trial registration Study 1: UMIN000049587 (November 23, 2022); Study 2: UMIN000049590 (November 23, 2022) (UMIN Clinical Trials Registry).

Download